Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sarepta Therapeutics, Inc.
< Previous
1
2
Next >
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
January 08, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 01, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
September 07, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
August 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
July 26, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
July 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
July 03, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
June 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
May 24, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 12, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
May 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
April 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
April 10, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.